David Sinclair· PhD
In human clinical trials, resveratrol (Res) alters AD biomarkers & preserves the blood-brain barrier, immune responses & activity of daily living scores.
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
In human clinical trials, resveratrol (Res) alters AD biomarkers & preserves the blood-brain barrier, immune responses & activity of daily living scores.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
resveratrol (1,000mg/day) improved cognitive function and lowered biomarkers of neuroinflammation in people with Alzheimer's disease.
There was a couple of studies, as you know, there's phase one and two clinical studies on Alzheimer's disease where they were given 500 milligrams or 1,000 milligrams of resveratrol a day and both of these studies found that there was a reduction in amyloid beta 42 in cerebral spinal fluid. There was an improvement in cognitive function and a couple of other parameters.